Dynavax Technolo Stock Price, News & Analysis

Dynavax (Nasdaq: DVAX) presented positive topline Part 1 data from its Phase 1/2 trial of shingles vaccine candidate Z-1018 at IDWeek 2025 and has initiated Part 2.

Key points: Z-1018 (multiple gE doses with CpG 1018 ± alum) showed anti-gE IgG and gE-specific CD4+ T-cell vaccine response rates comparable to Shingrix at four weeks after dose 2, plus robust polyfunctional CD4+ responses and a favorable tolerability profile. Dynavax advanced a 100 mcg gE + CpG 1018 + alum, 0/8-week regimen into Part 2, which has dosed first participants and plans ~324 adults aged 70+ with topline data expected in H2 2026.

Dynavax Technologies (Nasdaq: DVAX), a commercial-stage biopharmaceutical company focused on innovative vaccine development, will participate in a fireside chat at the 2025 Wells Fargo Healthcare Conference on September 3rd at 4:30 p.m. ET.

The company currently markets two key products: HEPLISAV-B, an approved hepatitis B vaccine for adults in the US, EU, and UK, and CpG 1018 adjuvant, which is used in HEPLISAV-B and various COVID-19 vaccines.

Dynavax Technologies (Nasdaq: DVAX) announced positive topline results from Part 1 of its Phase 1/2 clinical trial for Z-1018, its novel shingles vaccine candidate, demonstrating comparable efficacy to Shingrix with better tolerability. The trial's selected dose achieved a 100% humoral vaccine response rate and 89.7% cellular immune response rate.

Z-1018 showed significantly lower adverse reactions compared to Shingrix, with only 12.5% reporting grade 2-3 local reactions versus 52.6% for Shingrix, and 27.5% reporting grade 2-3 systemic reactions versus 63.2% for Shingrix. The company will advance the 100 mcg dose with CpG 1018 and alum adjuvant using an 8-week dosing interval to Part 2 of the trial in adults 70+ years, scheduled for 2H 2025.

Dynavax (NASDAQ:DVAX) reported strong Q2 2025 financial results, highlighted by record HEPLISAV-B quarterly net product revenue of $92 million, representing 31% year-over-year growth. The company refined its full-year 2025 HEPLISAV-B revenue guidance to $315-325 million.

Total Q2 revenues reached $95.4 million, with GAAP net income of $18.7 million ($0.16 per share). HEPLISAV-B's U.S. market share increased to 45%, up from 42% in Q2 2024. The company expects the U.S. hepatitis B vaccine market to expand to over $900 million in annual sales by 2030.

Key pipeline updates include anticipated top-line results from Phase 1/2 shingles vaccine trial in August 2025 and completed dosing in Part 1 of the pandemic influenza adjuvant program trial.

Dynavax Technologies (NASDAQ:DVAX), a commercial-stage biopharmaceutical company focused on innovative vaccine development, has scheduled its second quarter 2025 financial results announcement for Thursday, August 7, 2025, after U.S. market close.

The company will host a conference call and audio webcast at 4:30 p.m. ET/1:30 p.m. PT on the same day. Participants are advised to join approximately 10 minutes before the call starts. The webcast will be accessible through the company's investor relations website, with a replay available for 30 days.

Dynavax currently markets two commercial products: HEPLISAV-B vaccine for hepatitis B prevention and CpG 1018 adjuvant, which is used in multiple COVID-19 vaccines.

Dynavax Technologies Corporation (DVAX) announced that stockholders have elected all four director nominees - Brent MacGregor, Scott Myers, Lauren Silvernail, and Elaine Sun - to the Company's Board of Directors at their 2025 Annual Meeting. The preliminary voting results also indicate stockholder approval for all other Board-recommended proposals, including the phased declassification of the Board. The company views this outcome as validation of their strategic plan. The results remain preliminary until final tabulation and certification by the independent Inspector of Elections, with final results to be filed on Form 8-K with the SEC. Goldman Sachs & Co. LLC and Cooley LLP are serving as financial advisor and legal counsel, respectively.

Deep Track Capital, owning 14.82% of Dynavax Technologies (DVAX), issued a letter to shareholders advocating for the election of four nominees to the Board at the June 11, 2025 Annual Meeting. The letter highlights Dynavax's underperformance, including missed 2024 targets for Heplisav (U.S. sales of $268M vs $275M target, market share of 44% vs 47% target). The company's stock has underperformed the Nasdaq Biotechnology Index, falling 17% over one year and 15% over three years. Deep Track argues that without new board perspectives, critical questions about strategic direction and capital allocation will remain unaddressed. The investment firm defends its nominees' qualifications and long-term commitment, emphasizing their potential to bring valuable experience and investor perspective to address the company's challenges.

Dynavax Technologies (DVAX) urges stockholders to vote FOR all four of its director nominees at the June 11, 2025 Annual Meeting, opposing Deep Track's competing nominees. The company emphasizes its successful strategic repositioning since 2019, delivering a 203% total stockholder return over five years, significantly outperforming vaccine peers (9%) and the S&P Biotechnology Index (-17%). The board nominees - Brent MacGregor, Scott Myers, Lauren Silvernail, and Elaine Sun - bring critical expertise in biotech and vaccines. Independent proxy firms ISS and Egan-Jones support Dynavax's nominees, with ISS criticizing Deep Track's misleading TSR analysis. The company highlights HEPLISAV-B's market leadership, strong financial results, and successful business development generating over $950M in revenue (2020-2022). Dynavax has completed 85% of its $200M share repurchase program authorized in November 2024.

Dynavax Technologies (Nasdaq: DVAX), a commercial-stage biopharmaceutical company focused on innovative vaccine development, announced its upcoming presentation at William Blair's 45th Annual Growth Stock Conference on June 3rd at 2:40 p.m. CT. The presentation will be accessible via webcast through the company's investor relations website.

Dynavax currently markets two commercial products: HEPLISAV-B® vaccine, approved in the U.S., EU, and UK for hepatitis B virus prevention in adults 18 and older, and CpG 1018® adjuvant, which is used in HEPLISAV-B and various COVID-19 vaccines.